Australia markets closed

Inovio Pharmaceuticals, Inc. (INO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.8900+0.1600 (+9.25%)
At close: 04:00PM EDT
1.8800 -0.01 (-0.53%)
After hours: 07:57PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.7300
Open1.7700
Bid1.8500 x 38500
Ask1.8800 x 29200
Day's range1.7200 - 1.8900
52-week range1.3800 - 9.9600
Volume6,026,868
Avg. volume6,331,862
Market cap432.887M
Beta (5Y monthly)0.82
PE ratio (TTM)N/A
EPS (TTM)-1.5420
Earnings date08 Aug 2022 - 12 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.00
  • PR Newswire

    INOVIO Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced that in connection with the hiring of Dr. Michael John Sumner as Chief Medical Officer, announced on June 27, 2022, the Compensation Committee of INOVIO's Board of Directors approved equity grants to Dr. Sumner as inducement awards under INOVIO's 2022 Inducement Plan (the "In

  • Motley Fool

    Why Inovio Pharmaceuticals Stock Topped the Market on Monday

    Inovio Pharmaceuticals (NASDAQ: INO) stock rose slightly on an otherwise gloomy day for the wider market. Investors were cheered by the appointment of a new chief medical officer at their company. Previous to that, he worked in various positions at U.K. pharmaceutical company Shire in a stint that lasted roughly six years, and also held positions at Novartis and Novo Nordisk.

  • PR Newswire

    INOVIO Appoints Dr. Michael Sumner, MB BS, MBA as Chief Medical Officer

    INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced the appointment of Dr. Michael Sumner, MB BS, MBA, as Chief Medical Officer (CMO). Dr. Sumner will oversee INOVIO's clinical-stage pipeline of DNA medicines, global clinical development, clinical operations and biostatistics efforts, as well as regulatory affairs, pharmacovig